Press-release for stocks publishing date 2022 - 03

Prices are updated after-hours

trial publishing date : 2022 - 03 - 15

save search

An Inside Look: A Clinician’s Experience with the Waterlase Exclusive Trial Program
Published: 2022-03-15 (Crawled : 01:00) - biolase.com
BIOL | $0.144 -4.7% -3.85% 530K

Health Technology

| -56.25% | O: 3.13% H: 4.55% C: 2.42%
program trial

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic ShockOn track for top-line data in April 2022
Published: 2022-03-15 (Crawled : 20:00) - biospace.com/
WINT | $5.085 -10.53% -11.77% 51K

Health Technology

| 448.64% | O: 2.07% H: 4.17% C: -0.52%
phase 2 top-line data cardio star enroll topline

Global Industrial, Enterprise, Military, and Consumer Automation and Robotics Market Report 2022-2027: Unprecedented Efficiency and Effectiveness Gains will be Realized through 5G Robotics Solutions
Published: 2022-03-15 (Crawled : 16:00) - prnewswire.com
FNCTF | News | $11.16 1.13% -20.84% 0

Communications

| -0.53% | O: 0.71% H: 0.0% C: 0.0%
ISRG | $375.01 -0.55% -0.55% 990K

Health Technology

| 42.16% | O: 1.46% H: 1.19% C: 0.88%
trial solutions report 5g

Nektar Left Reassessing After Canceled Melanoma Trials
Published: 2022-03-15 (Crawled : 15:30) - biospace.com/
NKTR | News | $1.38 -2.82% -2.16% 960K

Health Technology

| -72.4% | O: -21.0% H: 13.67% C: 13.42%
als trials trial cel

Institute for Molecular Medicine Receives $12 Million NIH Grant to Fund Clinical Trials of AV-1959, First Preventive Vaccine for Alzheimer's Disease
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
FNCTF | News | $11.16 1.13% -20.84% 0

Communications

| -0.53% | O: 0.71% H: 0.0% C: 0.0%
av-1959 alzheimer als fun 2 million trials trial disease clinical trials molecular vaccine grant alzheimer’s alzheimer's disease alzheimer's

Dow to participate in J.P. Morgan Industrials Conference 2022
Published: 2022-03-15 (Crawled : 13:30) - prnewswire.com
DOW | $56.98 0.42% 0.32% 4M

Process Industries

| -5.47% | O: -0.68% H: 0.66% C: -1.67%
als trials trial conference

Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
REVB | $2.09 0.97% 1.43% 40K

| 104.9% | O: 9.8% H: 63.39% C: 11.61%
phase 2 phase 2b bioscience infection influenza enroll infections

MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| -8.67% | O: -3.03% H: 3.21% C: 3.21%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -4.94% | O: 3.07% H: 0.0% C: 0.0%
thio-101 phase 2 technology trial approval australia biotech iot

Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
Published: 2022-03-15 (Crawled : 13:30) - globenewswire.com
CHRS | $2.02 -7.34% -7.39% 630K

Health Technology

| -83.25% | O: 1.41% H: 5.81% C: 2.53%
hoice-01 treatment pos trial presentation cel positive results asco lung cancer positive therapy bioscience results cancer phase 3

Robotic Sensors Market - 47% Of Growth To Originate From APAC | Industrial Robots Segment To Be Significant For Revenue Generation | Technavio
Published: 2022-03-15 (Crawled : 13:00) - prnewswire.com
IFNNF | $33.5 2.48% -2.1% 1.3K

Electronic Technology

| 6.55% | O: -0.86% H: 0.0% C: 0.0%
SEKEY | $9.02 0.78% -1.89% 31K

Manufacturing

| 24.18% | O: 0.02% H: 1.58% C: 1.17%
IFNNY | $33.62 4.31% -2.12% 130K

Manufacturing

| 9.76% | O: -0.75% H: 3.29% C: 2.63%
TEL | News | $140.0 -2.26% 0.0% 5.8M

Electronic Technology

| 9.22% | O: -0.09% H: 0.06% C: -0.54%
HON | News 4 | $194.79 -0.7% -0.74% 2.3M

Producer Manufacturing

| 5.58% | O: 1.04% H: 0.0% C: 0.0%
NOVT | $157.81 -0.99% -0.94% 110K

Electronic Technology

| 27.53% | O: 1.02% H: 2.7% C: 2.43%
sensor trial origin growth

Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial
Published: 2022-03-15 (Crawled : 12:30) - globenewswire.com
ALEC | $5.25 -1.69% -1.33% 400K

Health Technology

| -61.14% | O: 1.85% H: 1.38% C: -5.38%
al001 ema phase 2 trial

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Published: 2022-03-15 (Crawled : 12:30) - biospace.com/
ARWR | $23.29 -2.06% -2.13% 810K

Health Technology

| -41.22% | O: 1.89% H: 2.65% C: 0.87%
treatment clearance phase 1 phase 2

Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.16 1.13% -20.84% 0

Communications

| -0.53% | O: 0.71% H: 0.0% C: 0.0%
MRK | $127.0 0.1% 0.63% 5.7M

Health Technology

| 63.28% | O: -0.13% H: 1.71% C: 1.24%
ylynk-010 keytruda lynparza prostate cancer state trial cancer

Better Therapeutics Announces Positive Primary Endpoint Data From Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients With Uncontrolled Type 2 Diabetes
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
BTTX | $0.0078 30.0% -65.02% 890K

| -99.75% | O: 9.38% H: 15.12% C: -29.57%
bt-001 pos control trial therapeutics diabetes positive

Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough
Published: 2022-03-15 (Crawled : 12:00) - prnewswire.com
TRVI | $2.68 -5.97% -6.34% 120K

Health Technology

| 100.76% | O: 2.27% H: 14.07% C: 8.15%
phase 2 trial therapeutics chronic cough enroll

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
AVXL | $3.41 -7.34% -8.24% 1.7M

Health Technology

| -66.17% | O: 0.4% H: 6.32% C: 5.24%
pdd-001 anavex phase 2 dementia anavex®2-73 parkinson conference presentation disease life science international tiona biomarkers

Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
SAGE | $14.0 8.11% 7.5% 2.5M

Health Technology

| -54.41% | O: 1.07% H: 2.93% C: 1.06%
sage-718 phase 2 air parkinson therapeutics presentation disease results

PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
Published: 2022-03-15 (Crawled : 12:00) - globenewswire.com
PDSB | $3.25 1.56% 1.84% 450K

Health Technology

| -36.02% | O: 0.2% H: 7.86% C: 7.27%
pds0101 phase 2 hpv trial cancer biotech iot tiona enroll

IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
IDYA | News | $39.85 2.13% 2.08% 1.4M

Health Technology